Cellectis Reports Encouraging Clinical Data from BALLI-01
Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab (FCA) with no...
Source: globenewswire.com
📰 Dose Level Three News
Dose Level Three News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dose Level Three. Real-time updates on events, politics, business and more.
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab with no Dose-Limiting Toxicities in BALLI-01... | December 11, 2021
Source: marketscreener.com